Search Results for: Charles Rice
Rice has received the 2016 InBev-Baillet Latour Health Prize for his fundamental discoveries in the field of infectious diseases. The award, given by the Baillet Latour Fund to recognize outstanding contributions in biomedical research for the benefit of human health, is Belgium’s most important scientific prize. More »
Granted by the Robert Koch Foundation, the annual award is one of Germany’s most distinguished scientific prizes and honors extraordinary accomplishments in infectious disease research. It recognizes Rice’s work on understanding the lifecycle of the hepatitis C virus and laying the groundwork for effective therapeutic developments. More »
This year’s Lasker-DeBakey Clinical Medical Research Award honors Charles M. Rice, who developed a system to study the replication of the virus that causes hepatitis C, an advance that has led to safe and powerful new drugs that cure the disease. The award, considered the most coveted American prize in medical science, will be presented on September 23 in New York City. More »
Rice, head of the Laboratory of Virology and Infectious Disease at Rockefeller, has been awarded the 100,000 euro prize for his description of the molecular and cellular basis of hepatitis C infection in humans.
Given by the Robert Koch Foundation, the annual award is one of Germany’s most prestigious scientific prizes, honoring extraordinary accomplishments in infectious disease research. Nussenzweig will share the €100,000 prize with Alberto Mantovani of Humanitas University for their achievements in immunology. More »
Both the virus and liver cells need the microRNA molecules the liver produces to regulate its genes. Researchers found that by co-opting one microRNA, the virus may cause changes in gene expression in liver cells. More »
Rockefeller fellow receives NIH ‘early independence award’ to study immune responses with high throughput sequencing
A 2012 graduate of the Tri-Institutional M.D.-Ph.D. program, Brad Rosenberg is one of 14 early-career investigators across the country to receive an NIH Director’s Early Independence Award, a five-year, $2.1 million grant that will allow him to establish his own research program at Rockefeller. More »
In 1990 researchers observed that most patients with hepatitis C also develop a rare autoimmune disease called mixed cryoglobulinemia, a condition that frequently leads to cancer, arthritis or both. Now scientists at Rockefeller University say that a decade-old explanation of how one disease causes the other is likely wrong, and instead offer a new — albeit controversial — theory of their own. More »
The Rockefeller University Center for Clinical and Translational Science (CCTS) has announced the recipients of its 2008 Pilot Project grants. Eight Rockefeller researchers will each receive $25,000 from the center to fund early studies in translational science that, if successful, might lead to clinical trials. More »
There’s infection and then there’s superinfection – when a cell already infected by a virus gets a second viral infection. But some viruses don’t like to share their cells. New research from Rockefeller University shows that the hepatitis C virus, which infects cells in the liver and can cause chronic liver disease, can block other hepatitis C variants from infecting the same cell. More »
A $50 million gift from the Starr Foundation, announced this week, will be used to create the Starr Fund for Collaborative Science at The Rockefeller University. The fund will promote and enhance scientific exchange and shared knowledge, and the university plans to use portions of the gift to implement several initiatives outlined in the university’s strategic plan, approved by Rockefeller’s Board of Trustees in 2005. More »
For many years scientists have struggled with an inability to efficiently culture the hepatitis C virus in the laboratory. Now, researchers at Rockefeller University have overcome several obstacles and successfully shown that a strain of HCV they created in the laboratory, which can efficiently be cultured in vitro, is also infectious in animals. More »
A team of researchers led by Rockefeller University immunologist Ralph M. Steinman, M.D., has been selected for a grant offer from the Foundation for the NIH (FNIH) of $14 million to support the design of novel vaccines that stimulate multiple components of the body’s immune response, including those that have been difficult to target with existing vaccine approaches. More »
The microbe that causes tuberculosis operates the way a human terrorist would. With minimal resources, the TB bacterium skillfully blends in and gains strength before lashing out unexpectedly.
Now, Rockefeller scientists John MacMicking, Ph.D., and John McKinney, Ph.D., have discovered a unique way the immune system can disarm the bacterial offender. If this defense could be strengthened, TB could be brought to biological justice. More »
Researchers at Rockefeller University and Washington University School of Medicine in St. Louis have identified mutations in a protein of certain strains of hepatitis C virus (HCV) that allow these strains to replicate more vigorously in human cell culture. The finding allows scientists to improve an essential tool for studying the virus and suggests a starting point for the design of effective vaccines. More »
First Hepatitis-C Center in Northeast Region Established By Rockefeller University, New York-Presbyterian, and Weill Cornell
New York, NY–Three neighboring New York City medical institutions–The Rockefeller University, NewYork-Presbyterian Hospital, and Weill Medical College of Cornell University–have jointly established the Center for the Study of Hepatitis C, the first major center in the Northeast region devoted specifically to the disease. Renowned virologist Charles M. Rice, Ph.D., who recently made the first infectious clone of the virus, will join The Rockefeller University faculty and serve as both scientific and executive director of the multi-institutional center. More »
Increasingly, scientists are finding that small RNA molecules might be effective targets for antiviral drugs. Using a new screening method, Rockefeller researchers now show that a number of RNA viruses need access to micro-RNAs produced by their host cells to replicate. More »
In devising a method to readily grow hepatitis C in the laboratory, scientists might have overcome a major hurdle for basic research into the virus and the disease it causes.